Evidence map›Paper›PMID 38421553›Full record

ArticleBreast cancer (Tokyo, Japan)2024

SIRT1 mediates breast cancer development and tumorigenesis controlled by estrogen-related receptor β.

Monalisa Parija, Surya Prakash, B Madhu Krishna, Sanghamitra Dash, Sandip K Mishra

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Sirtuins in Women's Health.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Histone acetylation modulators in breast cancer.Breast cancer research : BCR · 2025
    Review
  9. Review
  10. Acetylation of Histone H3 in Cancer Progression and Prognosis.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Monalisa Parija *Cancer Biology Lab, Gene Function and Regulation Group, Institute of Life Sciences, Nalco Square, Nadankanan Road, Kalinga Hospital Cross, Chandrasekharpur, Bhubaneswar, Odisha, 751023, India.
Surya Prakash *Cancer Biology Lab, Gene Function and Regulation Group, Institute of Life Sciences, Nalco Square, Nadankanan Road, Kalinga Hospital Cross, Chandrasekharpur, Bhubaneswar, Odisha, 751023, India.
B Madhu Krishna *Department of Medical Oncology, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.
Sanghamitra DashCancer Biology Lab, Gene Function and Regulation Group, Institute of Life Sciences, Nalco Square, Nadankanan Road, Kalinga Hospital Cross, Chandrasekharpur, Bhubaneswar, Odisha, 751023, India.
Sandip K MishraCancer Biology Lab, Gene Function and Regulation Group, Institute of Life Sciences, Nalco Square, Nadankanan Road, Kalinga Hospital Cross, Chandrasekharpur, Bhubaneswar, Odisha, 751023, India. sandipkmishra@ils.res.in.
Institute of Life Sciences · INRegional Centre for Biotechnology · INCity Of Hope National Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silent mating type information regulation 2 homolog 1 (SIRT1) is a class III histone deacetylase (HDAC) that is NAD + dependent and essential for metabolism, senescence, and cell survival. SIRT1 is overexpressed in several cancers, including breast cancer. SIRT1 is a well-known target gene of the estrogen receptor alpha (ER alpha) and is closely related to ER alpha deacetylation. Transcription factor Estrogen-related receptors (ERRs) share sequence homology with ERs in the DNA-binding domain, therefore, the possibility of sharing target genes between them is high. Our current research aims to gain insight into the function of ERRβ in regulating the activity of SIRT1 during the progression of breast cancer. ER-positive (ER + ve) breast cancer cells and tissues had considerably enhanced SIRT1 expression. Six potential ERRE sites were identified by analysis of the 5' upstream region of SIRT1, and both in vitro and in vivo experiments supported their presence. We found SIRT1 to be up-regulated in ERRβ overexpressed ER + ve breast cancer cells. Furthermore, our findings suggested that ectopic production of ERR and PCAF would increase SIRT1 activity. Our findings also indicated that ectopic production of ERRβ and PCAF increased SIRT1 activity. With sufficient evidence demonstrating the substantial involvement of SIRT1 in cell proliferation, migration, and colony formation capability, we were also able to illustrate the tumorigenic role of SIRT1. Overall, our findings highlight SIRT1's tumorigenic influence on breast cancer and suggest that SIRT1 inhibitors might serve as potential therapeutic drugs for the treatment of breast cancer.

Indexed as

Breast NeoplasmsGene Expression Regulation, NeoplasticReceptors, EstrogenSirtuin 1CarcinogenesisCell Line, TumorCell MovementCell ProliferationFemaleHumansMCF-7 CellsESRRB protein, humanReceptors, EstrogenSIRT1 protein, humanSirtuin 1Breast cancer proliferationEstrogen-related receptor βHDACSIRT1

Identifiers

PMID38421553
OpenAlexW4392298546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.